Intermolecular interactions of antimicrobial fluoroquinolones with purified rat liver CYP1A2 studied by proton nuclear magnetic resonance spectroscopy

References

• Butler M. A., Iwasaki M., Guengerich F. P., Kadlubar F. F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences, USA 1989; 86: 7696–7700
   PubMed Web of Science ®Google Scholar
• Crull G. B., Kennington J. W., Garber A. R., Ellis P. D., Dawson J. H. 19F Nuclear magnetic resonance as a probe of the spatial relationship between the heme iron of cytochrome P-450 and its substrate. Journal of Biological Chemistry 1989; 264: 2649–2655
   PubMed Web of Science ®Google Scholar
• Davis J. D., Aarons L., Houston J. B. Metabolism of theophylline and its inhibition by fluoroquinolones in rat hepatic microsomes. Xenobiotica 1995; 25: 563–573
   PubMed Web of Science ®Google Scholar
• Dawson J. H., Andersson L. A. A., Sono M. Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Journal of Biological Chemistry 1982; 257: 3606–3617
   PubMed Web of Science ®Google Scholar
• Distlerath L. M., Reilly P. E. B., Martin M. V., Davis G. G., Wilkinson G. R., Guengerich F. P. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 1985; 260: 9057–9067
   PubMed Web of Science ®Google Scholar
• Fuhr U., Wolff T., Harder S., Schymanski P., Staib A. H. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metabolism and Disposition 1990; 18: 1005–1010
   PubMed Web of Science ®Google Scholar
• Fuhr U., Strobl G., Manaut F., Anders E.-M., Sörgel F., Lopez-De-Brinas E., Chu D. T. W., Pernet A. G., Mahr G., Sanz F., Staib A. H. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Molecular Pharmacology 1993; 43: 191–199
   PubMed Web of Science ®Google Scholar
• Grohe K., Heitzer H. Cycloaracylation of enamines, I. Synthesis of 4-quinolone-3-carboxylic acids. 1987; 29–37, Liebigs Annalen der Chemie
   Google Scholar
• Guengerich F. P., Dannan G. A., Wright S. T., Martin M. V., Kaminsky L. S. Purification and characterization of liver microsomal cytochromes P-450: electrophoretric, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or β-naphthoflavone. Biochemistry 1982; 21: 6019–6030
   PubMed Web of Science ®Google Scholar
• Imai Y., Sato R. A gel-electrophoretically homogeneous preparation of cytochrome P-450 from liver microsomes of phenobarbital-pretreated rabbits. Biochemical and Biophysical Research Communications 1974; 60: 8–14
   PubMed Web of Science ®Google Scholar
• Kamataki T., Kitagawa H. Effects of lipid peroxidation on activities of drug-metabolizing enzymes in liver microsomes of rats. Biochemical Pharmacology 1973; 22: 3199–3207
   PubMed Web of Science ®Google Scholar
• Koga H., Itoh A., Murayama S., Suzue S., Irikura T. Structure-activity relationships of antibacterial 6, 7- and 7, 8-disubstituted 1-alkyl-1, 4-dihydro-4-oxoquinoline-3-carboxylic acids. Journal of Medicinal Chemistry 1980; 23: 1358–1363
   PubMed Web of Science ®Google Scholar
• Komori M., Hashizume T., Ohi H., Miura T., Kitada M., Nagashima K., Kamataki T. Cytochrome P-450 in human liver microsomes: high-performance liquid chromatographic isolation of three forms and their characterization. Journal of Biochemistry 1988; 104: 912–916
   PubMed Web of Science ®Google Scholar
• Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Lesca P., Lecointe P., Paoletti C., Mansuy D. Ellipticines as potent inhibitors of aryl hydrocarbon hydroxylase: their binding to microsomal cytochrome P450 and protective effect against benzo(a)pyrene mutagenicity. Biochemical Pharmacology 1978; 27: 1203–1209
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Ioannides C., Parke D. V. Molecular dimensions of the substrate binding site of cytochrome P-448. Biochemical Pharmacology 1986; 35: 2179–2185
   PubMed Web of Science ®Google Scholar
• Loft S., Otton S. V., Lennard M. S., Tucker G. T., Poulsen H. E. characterization of metronidazole metabolism by human liver microsomes. Biochemical Pharmacology 1991; 41: 1127–1134
   PubMed Web of Science ®Google Scholar
• Matsumoto J., Miyamoto T., Minamida A., Nishimura Y., Egawa H., Nishimura H. Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1, 6, 7-trisubstituted 1, 4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent. Journal of Medicinal Chemistry 1984; 27: 292–301
   PubMedGoogle Scholar
• Mildvan A. S., Gupta R. K. Nuclear relaxation measurements of the geometry of enzyme-bound substrates and analogs. Methods in Enzymology 1978; 49: 322–359
   PubMedGoogle Scholar
• Miyamoto T., Matsumoto J., Chiba K., Egawa H., Shibamori K., Minamida A., Nishimura Y., Okada H., Kataoka M., Fujita M., Hirose T., Nakano J. Synthesis and structure-activity relationships of 5-substituted 6, 8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. Journal of Medicinal Chemistry 1990; 33: 1645–1656
   PubMed Web of Science ®Google Scholar
• Mizuki Y., Kamaura M., Yamaguchi T., Sekine Y., Hashimoto M. Interaction of enoxacin with theophylline in rats. Arzneimittle Forschung/Drug Research 1989; 39: 593–597
   PubMed Web of Science ®Google Scholar
• Mizuki Y., Fujiwara I., Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. Journal of Antimicrobial Chemotherapy 1996; 37(suppl. A)41–55
   PubMedGoogle Scholar
• Modi S., Primrose W. U., Boyle J. M. B., Gibson C. F., Lian L., Roberts G. C. K. NMR studies of substrate binding to cytochrome P450BM3: comparisons to cytochrome P450cam. Biochemistry 1995; 34: 8982–8988
   PubMedGoogle Scholar
• Novak R. F., Vatsis K. P. 1H Fourier transform nuclear magnetic resonance relaxation rate studies on the interaction of acetanilide with purified isozymes of rabbit liver microsomal cytochrome P-450 and with cytochrome b5. Molecular Pharmacology 1982; 21: 701–709
   PubMed Web of Science ®Google Scholar
• Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. Journal of Biological Chemistry 1964; 239: 2379–2385
   PubMed Web of Science ®Google Scholar
• Pelkonen O., Puurunen J. The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat. Biochemical Pharmacology 1980; 29: 3075–3080
   PubMed Web of Science ®Google Scholar
• Phillips A. H., Langdon R. G. Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. Journal of Biological Chemistry 1962; 237: 2652–2660
   PubMed Web of Science ®Google Scholar
• Rodrigues A. D., Gibson G. G., Ioannides C., Parke D. V. Interactions of imidazole antifungal agents with purified cytochrome P-450 proteins. Biochemical Pharmacology 1987; 36: 4277–4281
   PubMed Web of Science ®Google Scholar
• Sarkar M., Polk R. E., Guzelian P. S., Hunt C., Karnes H. T. In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrobial Agents and Chemotherapy 1990; 34: 594–599
   PubMed Web of Science ®Google Scholar
• Sarkar M. A., Hunt C., Guzelian P. S., Karnes H. T. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metabolism and Disposition 1992; 20: 31–37
   PubMed Web of Science ®Google Scholar
• Shimizu T., Md Sadeque A. J., Sadeque G. N., Hatano M., Fujii-Kuriyama Y. Ligand binding studies of engineered cytochrome P-450d wild type, proximal mutants, and distal mutants. Biochemistry 1991; 30: 1490–1496
   PubMed Web of Science ®Google Scholar
• Solomon I., Bloembergen N. Nuclear magnetic interactions in the HF molecule. Journal of Chemical Physics 1956; 25: 261–266
   Web of Science ®Google Scholar
• Tassaneeyakul W., Birkett D. J., Veronese M. E., McManus M. E., Tukey R. H., Quattrochi L. C., Gelboin H. V., Miners J. O. Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics 1993; 265: 401–407
   PubMed Web of Science ®Google Scholar
• Thomas P. E., Reik L. M., Ryan D. E., Levin W. Induction of two immunochemically related rat liver cytochrome P-450 isozymes, cytochrome P-450c and P-450d, by structurally diverse xenobiotics. Journal of Biological Chemistry 1983; 258: 4590–4598
   PubMed Web of Science ®Google Scholar
• Valero F., De La Torre R., Segura J. Selective in-vitro inhibition of hepatic oxidative metabolism by quinolones: 7-ethoxyresorufin and caffeine as model substrates. Journal of Pharmacy and Pharmacology 1991; 43: 17–21
   PubMed Web of Science ®Google Scholar
• Van De Straat R., De Vries J., De Boer H. J. R., Vromans R. M., Vermeulen N. P. E. Relationship between paracetamol binding to and its oxidation by two cytochromes P-450 isozymes—a proton nuclear magnetic resonance and spectrophotometric study. Xenobiotica 1987; 17: 1–9
   PubMed Web of Science ®Google Scholar
• Yasukochi Y., Masters B. S. S. Some properties of detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. Journal of Biological Chemistry 1976; 251: 5337–5344
   PubMed Web of Science ®Google Scholar